for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Avid Bioservices Inc

CDMO.OQ

Latest Trade

5.88USD

Change

0.00(0.00%)

Volume

70,094

Today's Range

5.81

 - 

6.04

52 Week Range

3.39

 - 

7.23

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.88
Open
5.81
Volume
70,094
3M AVG Volume
10.87
Today's High
6.04
Today's Low
5.81
52 Week High
7.23
52 Week Low
3.39
Shares Out (MIL)
56.24
Market Cap (MIL)
326.18
Forward P/E
-29.00
Dividend (Yield %)
--

Latest Developments

More

Avid Bioservices Reports Q1 Loss Per Share $0.08

Avid Bioservices Enters Into Contract Manufacturing Agreements With New And Existing Customers

Avid Bioservices Reports Q4 Loss Per Share $0.02

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Avid Bioservices Inc

Avid Bioservices, Inc., formerly Peregrine Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The Company also provides a variety of process development activities, including cell line development and optimization.

Industry

Biotechnology & Drugs

Contact Info

2642 Michelle Dr Ste 200

+1.714.5086100

http://avidbio.com/

Executive Leadership

Joseph Carleone

Non-Executive Chairman of the Board

Richard B Hancock

Interim President, Chief Executive Officer, Director

Daniel Ryan Hart

Chief Financial Officer

Stephen Michael Hedberg

Chief Accounting Officer

Mark R Ziebell

Vice President, General Counsel, Corporate Secretary

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.1K

2018

0.1K

2019

0.1K

2020(E)

0.1K
EPS (USD)

2017

-0.880

2018

-0.510

2019

-0.160

2020(E)

-0.200
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.80
Price To Book (MRQ)
6.57
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-9.47
Return on Equity (TTM)
-6.70

Latest News

BRIEF-Avid Bioservices Provides Update On Ongoing Expansion Of Process Development Capabilities And Laboratory Infrastructure

* AVID BIOSERVICES PROVIDES UPDATE ON ONGOING EXPANSION OF PROCESS DEVELOPMENT CAPABILITIES AND LABORATORY INFRASTRUCTURE

BRIEF-Avid Bioservices Selected By Acumen Pharmaceuticals To Lead Process Development And Clinical Manufacture Of Novel Alzheimer's Disease Candidate

* AVID BIOSERVICES SELECTED BY ACUMEN PHARMACEUTICALS TO LEAD PROCESS DEVELOPMENT AND CLINICAL MANUFACTURE OF NOVEL ALZHEIMER’S DISEASE CANDIDATE

BRIEF-Avid Bioservices Announces Proposed Offering Of Common Stock

* AVID BIOSERVICES ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

BRIEF-Avid Bioservices, Oncologie Enter Into Asset Assignment, Purchase Agreement For Avid's PS-Targeting Program Including Bavituximab

* AVID BIOSERVICES AND ONCOLOGIE ENTER INTO ASSET ASSIGNMENT AND PURCHASE AGREEMENT FOR AVID’S PS-TARGETING PROGRAM INCLUDING BAVITUXIMAB

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up